Cytek Biosciences, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48.1M | $44.1M | $62.1M | $52.3M | $45.6M | $41.5M | $57.5M | $51.5M |
| Cost of Revenue | $19.8M | $22.9M | $29.3M | $24.7M | $21.7M | $21.3M | $23.8M | $22.5M |
| Gross Profit | $28.3M | $21.3M | $32.9M | $27.6M | $23.9M | $20.2M | $33.7M | $29.0M |
| Gross Margin | 58.9% | 48.2% | 52.9% | 52.7% | 52.3% | 48.6% | 58.5% | 56.3% |
| Operating Expenses | ||||||||
| Research & Development | $9.7M | $9.6M | $9.0M | $9.0M | $8.8M | $9.7M | $9.7M | $9.9M |
| SG&A Expense | $16.8M | $18.5M | $16.4M | $16.1M | $13.5M | $12.9M | $9.1M | $10.9M |
| Operating Income | $-11.4M | $-18.5M | $-5.6M | $-9.2M | $-10.6M | $-15.0M | $3.0M | $-4.2M |
| Operating Margin | -23.7% | -41.8% | -9.0% | -17.6% | -23.3% | -36.1% | 5.2% | -8.2% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | $-4.0M | $-7.8M | $-6.8M | $-11.3M | $10.3M | $157.0K |
| Income Tax Expense | $515.0K | $1.5M | $40.0M | $-2.3M | $-1.2M | $136.0K | $680.0K | $-784.0K |
| Net Income | $-12.2M | $-18.9M | $-44.1M | $-5.5M | $-5.6M | $-11.4M | $9.6M | $941.0K |
| Net Margin | -25.3% | -42.7% | -70.9% | -10.5% | -12.2% | -27.5% | 16.8% | 1.8% |
| EPS (Basic) | $-0.09 | $-0.15 | $-0.35 | $-0.04 | $-0.04 | $-0.09 | $0.07 | $0.01 |
| EPS (Diluted) | $-0.09 | $-0.15 | $-0.35 | $-0.04 | $-0.04 | $-0.09 | $0.07 | $0.01 |
| Shares Outstanding (Basic) | 129.5M | 128.7M | 127.7M | 127.5M | 126.9M | 128.3M | 130.6M | 131.0M |
| Shares Outstanding (Diluted) | 129.5M | 128.7M | 127.7M | 127.5M | 126.9M | 128.3M | 130.6M | 132.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |